Disruptive Pharma
@guardtherapeutics.com
Vår vision är att rädda liv. Därför är vi dedikerade till att utveckla morgondagens läkemedel mot oxidativ stress, något som väsentligen bidrar till möjligheten att rädda liv men också besitter potential att förebygga och behandla allvarliga njursjukdomar.
Disruptive Pharma's Company Logos
Disruptive Pharma's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#3AB0C3
Pelorous
58, 176, 195
188, 54, 50
70, 10, 0, 24
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#263C4F
Rhino
38, 60, 79
208, 35, 23
52, 24, 0, 69
About Disruptive Pharma
Guard Therapeutics is a Swedish biotechnology company dedicated to developing innovative therapies for diseases that require more effective treatments. Their lead clinical drug candidate, RMC-035, is being developed as a kidney-protective treatment for open-heart surgery and kidney transplantation. With a strong focus on research and development, Guard Therapeutics aims to leverage the body's own defense mechanisms against oxidative stress to protect, clean, and repair vulnerable cells and tissues.
The global phase 2 study for RMC-035, called AKITA, began in early 2022. The market for acute kidney injuries is significant, affecting 13 million individuals worldwide annually. Through their targeted approach and powerful scientific concept, Guard Therapeutics is committed to saving lives and providing better treatment options for patients in need.
Guard Therapeutics is listed on the Nasdaq First North Growth Market Stockholm. For more information about their clinical development and their vision to save lives, visit their website
Related Brands
Tags
A1M-based therapeutics
Kidney disease drug development
Peptide therapeutics
Clinical-stage biotechnology
